scholarly journals INFLUENCE OF A NOVEL ADAMANTANE DERIVATIVE OF GABA ON THE NEUROLOGICAL DEFICIT OF RATS WITH BRAIN ISCHEMIA

2021 ◽  
pp. 5-5
Author(s):  
N.S. Kovalev ◽  
D.A. Bakulin ◽  
D.V. Kurkin ◽  
E.E. Abrosimova ◽  
L.A. Sablina ◽  
...  
Keyword(s):  
Brain Ischemia ◽  
Neurological Deficit ◽  
Adamantane Derivative

Neurological disorders in animals with cerebral ischemia and diabetes mellitus and their correction by a new agonist gpr119 and its combinations with metformin and citicoline

2019 ◽  
pp. 96-104
Author(s):  
Д.А. Бакулин ◽  
Д.В. Куркин ◽  
Е.В. Волотова ◽  
Е.О. Логвинова ◽  
К.А. Авдиенко ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Cerebral Ischemia ◽  
Glycemic Control ◽  
Brain Ischemia ◽  
Combination Treatment ◽  
Neurological Deficit ◽  
Neurological Disorders ◽  
Control Group ◽  
Gpr119 Agonist ◽  
Hypoglycemic Therapy

Сахарный диабет (СД) 2 типа значительно повышает риск развития инсульта и выбор гипогликемической терапии может оказать влияние не только на вероятность развития, но и на тяжесть течения нарушения мозгового кровообращения (НМК). Цель: оценить влияние комбинированного введения агониста GPR119 с метформином и цитиколином на выраженность психоневрологических нарушений у животных с НМК на фоне СД. Методика. Исследование проведено на крысах линии Wistar, которым моделировали фокальную ишемию ГМ на фоне 28 дневного стрептозотоцин-никотинамид-индуцированного СД. Агонист рецептора GPR119 (дипиарон) и его комбинацию с метформином вводили с первого дня развития СД, а цитиколин - после моделирования НМК. Психоневрологические нарушения оценивались с использованием шкал «Combs & D’Alecy» и «Garcia», и тестов «Открытое поле», «Ротарод», УРПИ и ТЭИ. Результаты и обсуждение. Введение метформина приводило к нормализации уровня гликемии, но не снижало выраженность неврологического дефицита при последующем моделировании НМК. По сравнению с контролем в группах, получавших дипиарон и в большей степени его комбинацию с метформином, помимо улучшения контроля гликемии наблюдалось значительное снижение объема инфаркта и отёка мозга, а также выраженности психоневрологических нарушений у выживших животных (p<0,05). Введение цитиколина без гипогликемической терапии не приводило к снижению уровня неврологического дефицита по сравнению с контрольной группой, при этом добавление цитиколина к гипогликемической терапии значимо не снижало тяжесть течения НМК. Заключение. Комбинированное введение агониста GPR119 и метформина животным с экспериментальной ишемией ГМ на фоне СД значительно повышает терапевтический потенциал обоих препаратов, обеспечивая лучший контроль уровня гликемии и снижая выраженность психоневрологического дефицита при моделировании НМК. Type 2 diabetes mellitus (DM2) significantly increases the risk of stroke, and the choice of hypoglycemic therapy may influence not only a probability of stroke but also severity of cerebrovascular disease. Objective: To evaluate the effect of combination treatment with a GPR119 agonist, metformin and citicoline on severity of neurological disorders in animals with stroke and diabetes. Cerebral ischemia was modeled by intraluminal occlusion of the middle cerebral artery (OMCA). Methods. The study was performed on Wistar rats with 28-day streptozotocin-nicotinamide-induced diabetes. The GPR119 receptor agonist (dipiaron) and its combination with metformin were administered starting from the first day of DM, and citicoline was administered after the induction of brain ischemia. Behavioral and neurological disorders were evaluated using the Combs & D’Alecy and Garcia scales, and the open field, Rotarod, and active and passive avoidance tests. Results. The metformin treatment normalized glycemia but did not alleviate severity of the neurological deficit induced by subsequent OMCA. The groups treated with dipiaron and its combination with metformin, in addition to improved glycemic control, showed significant decreases in brain infarction volume and edema and the severity of neurological disorders in surviving animals compared to the control (p<0.05). Administration of citicoline without the hypoglycemic therapy reduced the neurological deficit in comparison with the control group. Addition of citicoline to the hypoglycemic therapy did not significantly reduce the severity of brain ischemia. Conclusion. The combination treatment of animals with brain ischemia and diabetes with the GPR119 agonist and metformin significantly enhanced the therapeutic potential of both drugs evident as a better glycemic control and alleviated severity of the neurological deficit following OMCA.

scholarly journals CEREBROPROTECTIVE ACTIVITY OF NOVEL ADAMANTANE DERIVATIVE OF 2-PYRROLIDONE IN RATS WITH BRAIN ISCHEMIA

2021 ◽  
Vol 77 (1) ◽  
pp. 98-101
Author(s):  
N.S. Kovalev ◽  
◽  
D.A. Bakulin ◽  
D.V. Kurkin ◽  
M.A. Dubrovina ◽  
...  
Keyword(s):  
Brain Ischemia ◽  
Adamantane Derivative ◽  
Cerebroprotective Activity

scholarly journals Relationship between the induction of inflammatory processes and infectious diseases in patients with ischemic stroke.

2013 ◽  
Vol 60 (3) ◽  
Author(s):  
Marek Cieślak ◽  
Andrzej Wojtczak ◽  
Michał Cieślak
Keyword(s):  
Ischemic Stroke ◽  
Survival Rate ◽  
Cerebral Ischemia ◽  
Infectious Diseases ◽  
Inflammatory Cytokines ◽  
Brain Ischemia ◽  
Neurological Deficit ◽  
Interleukin 1 ◽  
Inflammatory Processes ◽  
Pro Inflammatory Cytokines

Pro-inflammatory cytokines participate in the induction of ischemic stroke. So far, their participation in the cerebral ischemia was proven for the tumor necrosis factor TNF-α, interleukin-1 (IL-1), and interleukin-6 (IL-6). The release of the pro-inflammatory cytokines into the extracellular space causes the enlargement of the brain damage region, and consequently increases the neurological deficit and negatively affects the survival rate prognoses. That is confirmed by the increased concentration of pro-inflammatory cytokines in blood and the cerebrospinal fluid of patients with brain stroke, as well as by the research on the induced/experimental cerebral ischemia in animals. The pro-inflammatory cytokines participate in the migration of the reactive T lymphocytes to the regions of brain ischemia where they enhance the nerve tissue damage by down-regulation of microcirculation, induce the pro-thrombotic processes and release other neurotoxic cytokines. Also, in the early stage of cerebral ischemia, cytokines activate the axis hypothalamus-pituitary gland-adrenal cortex and increase the cortisol concentration in blood, what results in the decreased resistance to infectious diseases. Administration of the inhibitor of the interleukin-1 receptor (IL-1Ra) inhibits the inflammatory processes in the region of brain ischemia, and subsequently improves the prognosis for the size of the neurological deficit and the survival rate, as well as resistance to infectious diseases.

scholarly journals Cerebrovascular and Neuroprotective Effects of Adamantane Derivative

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Ruben S. Mirzoyan ◽  
Tamara S. Gan’shina ◽  
Denis V. Maslennikov ◽  
Georgy I. Kovalev ◽  
Ivan A. Zimin ◽  
...  
Keyword(s):  
Blood Flow ◽  
Nmda Receptors ◽  
Middle Cerebral Artery ◽  
Brain Tissue ◽  
Cerebral Artery ◽  
Brain Ischemia ◽  
Adamantane Derivative ◽  
Neuroprotective Activity ◽  
Neuroprotective Effects ◽  
The Brain

Objectives. The influence of 5-hydroxyadamantane-2-on was studied on the rats’ brain blood flow and on morphological state of brain tissue under the condition of brain ischemia. The interaction of the substance with NMDA receptors was also studied.Methods. Study has been implemented using the methods of local blood flow registration by laser flowmeter, [3H]-MK-801binding, and morphological examination of the brain tissue. We used the models of global transient ischemia of the brain, occlusion of middle cerebral artery, and hypergravity ischemia of the brain.Results. Unlike memantine, antagonist of glutamatergic receptors, the 5-hydroxyadamantane-2-on does not block NMDA receptors but enhances the cerebral blood flow of rats with brain ischemia. This effect is eliminated by bicuculline. Under conditions of permanent occlusion of middle cerebral artery, 5-hydroxyadamantane-2-on has recovered compensatory regeneration in neural cells, axons, and glial cells, and the number of microcirculatory vessels was increased. 5-Hydroxyadamantane-2-on was increasing the survival rate of animals with hypergravity ischemia.Conclusions. 5-Hydroxyadamantane-2-on, an adamantane derivative, which is not NMDA receptors antagonist, demonstrates significant cerebrovascular and neuroprotective activity in conditions of brain ischemia. Presumably, the GABA-ergic system of brain vessels is involved in mechanisms of cerebrovascular and neuroprotective activity of 5-hydroxyadamantane-2-on.

Post-ischemic gene transfer of IL-10 protects against global brain ischemia

2005 ◽  
Vol 25 (1_suppl) ◽  
pp. S507-S507 ◽  
Author(s):  
Takashi Shichita ◽  
Hiroaki Ooboshi ◽  
Yasuhiro Kumai ◽  
Masahiro Kumai ◽  
Junichi Takada ◽  
...  
Keyword(s):  
Gene Transfer ◽  
Brain Ischemia ◽  
Global Brain Ischemia ◽  
Global Brain

Quantitative evaluation of the neuroprotective effects of thiopental sodium, propofol and halothane on brain ischemia in gerbils: Use of a logistic regression curve

2005 ◽  
Vol 25 (1_suppl) ◽  
pp. S297-S297
Author(s):  
Motomu Kobayashi ◽  
Yoshimasa Takeda ◽  
Ken Takata ◽  
Hisami Aoe ◽  
Kiyoshi Morita
Keyword(s):  
Logistic Regression ◽  
Quantitative Evaluation ◽  
Brain Ischemia ◽  
Regression Curve ◽  
Neuroprotective Effects ◽  
Thiopental Sodium

THE USE OF ALTERNATIVE AND CLASSICAL TECHNOLOGIES IN THE REHABILITATION OF PATIENTS WITH CHRONIC BRAIN ISCHEMIA

Fitoterapia ◽  
2019 ◽  
Vol 2 (2) ◽  
pp. 44-45
Author(s):  
L. V. Andriyuk ◽  
◽  
A. V. Yermolaieva ◽  
N. V. Matsko ◽  
O. V. Grabous ◽  
...  
Keyword(s):  
Brain Ischemia ◽  
Chronic Brain Ischemia
Sign in / Sign up

Export Citation Format

Share Document